Praxis Precision Medicines (PRAX) is down about 3% in Wednesday trading (April 15, 2026), giving back a portion of the prior session’s gains after the FDA accepted the company’s New Drug Application (NDA) for ulixacaltamide HCl in adult essential tremor. The FDA set a target action date of January 29, 2027 under PDUFA, and the agency indicated it does not plan to hold an advisory committee meeting for the application. (investing.com)

The day-after pullback looks driven by positioning and profit-taking following a fast move higher into the FDA acceptance headline and the stock trading near recent highs. With the regulatory milestone now public, near-term trading is shifting toward the next catalyst window rather than repricing the acceptance itself.

Attention now turns to the American Academy of Neurology (AAN) Annual Meeting in Chicago (April 18–22, 2026), where Praxis plans multiple presentations, including expanded analyses from the Phase 3 Essential3 program and a plenary session on Tuesday, April 21, 2026. Traders will be focused on whether any additional details on durability, safety, and functional endpoints change the market’s expectations into the FDA review. (globenewswire.com)

With the NDA accepted and a PDUFA clock running to January 29, 2027, the stock’s next leg is likely to depend on incremental clinical detail at AAN and any updates on commercialization planning and launch readiness. Until then, PRAX trading may remain volatile as short-term holders rotate out following the post-acceptance spike while longer-term investors wait for additional data color and regulatory milestones. (investing.com)